ASIA BEAT: Getting used to bad news
This article was originally published in Scrip
Executive Summary
Any outside observer scanning the pharma news flow from Asia over the past few weeks would be justified in concluding the sector to be characterized solely by broad corporate malfeasance or at least alleged wrongdoing in one form or another.